Why is AST less specific than ALT for liver disease?

AST is found in liver, heart, skeletal muscle, kidney, brain, and red blood cells, so an isolated AST elevation can reflect myocardial infarction, muscle injury, haemolysis, or other non-hepatic conditions. ALT is far more concentrated in liver tissue, making it the more liver-specific marker.

Can AST be elevated without liver disease?

Yes. Strenuous exercise, skeletal muscle injury, rhabdomyolysis, myocardial infarction, cardiac procedures, and haemolysis all raise AST. Concurrent creatine kinase and troponin measurements help distinguish muscle and cardiac sources from hepatic injury.

Is fasting required for an AST test?

No. AST does not require fasting, though it is often part of a metabolic panel that may specify fasting for glucose and lipid measurements.

What does a very high AST indicate?

AST above 1000 U/L usually indicates acute hepatocellular injury — viral hepatitis, ischaemic (shock) liver, drug-induced or toxic hepatitis, or acute bile-duct obstruction. The pattern with ALT, the ratio, and the clinical context guide the differential.

Does vitamin B6 deficiency affect AST results?

Yes. AST requires pyridoxal-5'-phosphate as a cofactor, so B6 deficiency lowers measured activity and can mask true tissue injury. This is particularly relevant in patients with alcohol use disorder or malnutrition.

Why should patients avoid heavy exercise before the test?

AST is present in skeletal muscle, so strenuous exercise or muscle trauma can raise it independently of liver disease. Avoiding vigorous activity before the draw reduces the chance of a muscle-related elevation.

How long do AST results take?

Results are typically available within 1–2 business days from specimen receipt at the processing laboratory.

BML-GAS-059gastrointestinalUSA

Aspartate Aminotransferase (AST) Test

Q: Can AST be normal in someone with cirrhosis?

Yes. Advanced cirrhosis can present with normal or only mildly elevated aminotransferases, so a normal AST does not exclude significant liver disease. The full liver panel, including albumin, bilirubin, and INR, provides a more complete picture.

The AST test measures serum aspartate aminotransferase, an enzyme present in liver, heart, skeletal muscle, and other tissues. It is a sensitive but non-specific marker of cellular injury, interpreted with ALT to calculate the AST:ALT ratio, which distinguishes steatotic (ratio <1) from alcohol-related (ratio >2) liver disease, and with CK and troponin to separate hepatic from muscle and cardiac…

Biomarkers

Blood (serum)

Sample

1–2 business days

Turnaround

Fasting

What is the AST test?

The Aspartate Aminotransferase (AST) Test measures the serum activity of an enzyme present in multiple tissues, most notably liver, heart, and skeletal muscle. Practitioners order AST primarily as part of the liver panel to assess hepatocellular injury, but its broader tissue distribution makes it a complementary rather than standalone marker. It is rarely ordered alone; instead, it is interpreted alongside ALT to calculate the AST:ALT ratio, with CK and troponin to distinguish muscle and cardiac sources, and with alkaline phosphatase, GGT, and bilirubin to characterise the pattern of liver injury. AST adds discriminatory power that ALT cannot provide on its own: the ratio differentiates causes of hepatocellular damage, and the release of mitochondrial AST in severe injury gives prognostic information. Serial AST measurements track disease activity in chronic liver conditions and monitor response to hepatotoxic drugs, while acute elevations prompt urgent evaluation for ischaemic hepatitis, viral hepatitis, or drug toxicity.

What does the AST test measure?

AST(Aspartate Aminotransferase)

Range: Approximately 10–40 U/L, sex- and assay-dependent.Optimal: Optimal thresholds mirror those for ALT in the hepatic context, with some sources favouring upper limits around 30–35 U/L; however, AST's presence in non-hepatic tissues means that 'optimal' varies by clinical question.U/L / µkat/L

Aspartate aminotransferase is a pyridoxal-phosphate-dependent enzyme that catalyses reversible transfer of an amino group from aspartate to alpha-ketoglutarate, generating oxaloacetate and glutamate. Two isoforms exist: a cytosolic and a mitochondrial form. The enzyme is concentrated in liver, cardiac muscle, skeletal muscle, kidney, brain, and red blood cells. Because hepatocytes contain both isoforms and mitochondrial AST is released when injury is severe, AST elevation reflects both the site and the severity of tissue damage. Its plasma half-life is shorter than that of ALT, typically around 17 hours, so AST normalises more quickly after acute injury resolves.

AST is a sensitive but non-specific marker of tissue injury. In the liver it is released in hepatocellular damage alongside ALT, but because it is also abundant in myocardium and skeletal muscle, an isolated AST rise may point to cardiac ischaemia, myositis, or haemolysis rather than hepatic disease. The AST:ALT ratio is central to interpretation — a ratio below one suggests steatotic liver disease, a ratio above two favours alcohol-related hepatocellular injury, and a ratio near or above one with very high absolute values is seen in acute ischaemic or toxic hepatitis. AST is therefore interpreted in tandem with ALT, CK, troponin, and the rest of the liver panel.

Why is the AST test ordered?

Evaluation of suspected hepatocellular injury, interpreted with ALT, ALP, GGT, and bilirubin to classify the pattern and guide differential diagnosis
Assessment of the AST:ALT ratio in patients with known or suspected alcohol-related liver disease or metabolic dysfunction-associated steatotic liver disease
Investigation of markedly elevated transaminases to distinguish acute viral, ischaemic, or toxic hepatitis from chronic processes
Monitoring of chronic liver disease progression and response to therapy, where serial trends provide more information than single values
Baseline and interval assessment of patients receiving potentially hepatotoxic or myotoxic medications, such as statins, where both AST and CK inform the differential
Differentiation of liver injury from myocardial infarction or skeletal muscle disease when AST is elevated in isolation, using troponin and CK
Work-up of suspected haemochromatosis, Wilson disease, or autoimmune hepatitis, where the aminotransferase pattern and ratio add context to specific diagnostic tests
Prognostic evaluation in acute liver injury, where very high AST with a rising ratio may indicate severe mitochondrial damage and poorer short-term outcomes

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days

Collection notes

Phlebotomy at the processing laboratory's draw site (LabCorp, Quest, or Boston Heart Diagnostics, depending on routing). No special preparation is required, though patients should avoid strenuous physical activity shortly before the draw to reduce exercise-related muscle release. Reject grossly haemolysed specimens.

Specimen requirements

Minimum 0.5 mL serum (gel separator acceptable). Separate from cells promptly; AST is stable refrigerated for several days. Note the performing laboratory for serial comparability, as reference limits differ.

What can affect AST results?

elevatesSkeletal muscle injury and strenuous exercise

AST is abundant in skeletal muscle, so vigorous exercise, trauma, intramuscular injections, and rhabdomyolysis can raise AST disproportionately to ALT; concurrent CK measurement resolves the source.

elevatesHaemolysis

Red blood cells contain AST, so haemolysed specimens yield falsely elevated results; grossly haemolysed samples should be rejected and a fresh specimen obtained.

elevatesMyocardial infarction and cardiac procedures

Cardiomyocytes are rich in AST, so acute myocardial infarction or cardiac surgery raises AST; troponin and ECG distinguish cardiac from hepatic sources.

reducesPyridoxine (vitamin B6) deficiency

AST activity depends on pyridoxal-5'-phosphate as a cofactor, so B6 deficiency lowers measured activity and can mask true tissue injury, particularly in patients with alcohol use disorder or malnutrition.

elevatesMacroenzyme formation

Rarely, AST binds to immunoglobulin or forms a high-molecular-weight complex, producing persistent unexplained elevation without tissue injury; polyethylene glycol precipitation or gel filtration can confirm a macroenzyme.

elevatesObesity and hepatic steatosis

Chronic low-grade hepatocellular injury from steatosis elevates both aminotransferases, usually with AST less than ALT (ratio <1); the pattern helps identify metabolic dysfunction-associated steatotic liver disease.

What do AST results mean?

Elevated

Hepatocellular injury (viral, autoimmune, steatotic, drug-induced, ischaemic, or toxic hepatitis); skeletal muscle injury (exercise, trauma, myositis, rhabdomyolysis); myocardial infarction; haemolysis (in vitro or in vivo); and less commonly pancreatitis, renal infarction, or macroenzyme. The AST:ALT ratio narrows the differential: <1 suggests steatotic liver disease, >2 suggests alcohol-related injury, and very high absolute values (>1000 U/L) point to acute viral, ischaemic, or toxic hepatitis. CK and troponin distinguish muscle and cardiac sources.

Normal

A normal AST does not exclude significant liver disease — advanced cirrhosis and compensated chronic hepatitis can present with near-normal aminotransferases. Normal AST in the presence of elevated ALP suggests cholestatic rather than hepatocellular injury. Always interpret AST in the context of the full liver panel, CK, and the clinical picture.

Reduced

Low AST is uncommon and usually not clinically significant. It may be seen with pyridoxine deficiency, uraemia, or in very frail, sarcopenic patients. A low result can mask concurrent injury if a cofactor deficiency is present.

Note: AST must be interpreted alongside ALT to calculate the ratio, with CK to exclude muscle sources, and with the rest of the liver panel (ALP, GGT, bilirubin, albumin) to classify the injury pattern. Magnitude, trend, and chronicity matter more than a single value. Reference intervals differ between laboratories, so serial monitoring is best performed at the same site. Very high AST with a rising AST:ALT ratio in acute injury suggests mitochondrial release and may carry prognostic weight.

Frequently asked questions

The AST:ALT ratio helps identify the cause of liver injury. A ratio below one is typical of metabolic dysfunction-associated steatotic liver disease, while a ratio above two suggests alcohol-related hepatocellular injury. Very high absolute values with a rising ratio indicate severe mitochondrial damage.

How to access the AST test

The AST reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Kwo PY, et al. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. (2017)
Nyblom H, et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int. (2006)
Sheth SG, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. (1998)
Rinella ME, et al. AASLD practice guidance on the clinical assessment and management of NAFLD/MASLD. Hepatology. (2023)
Cohen JA, Kaplan MM. The SGOT/SGPT ratio — an indicator of alcoholic liver disease. Dig Dis Sci. (1979)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

gastrointestinal

ALT

The ALT test measures serum alanine aminotransferase, a cytosolic hepatocyte enzyme released during liver cell injury and the most liver-specific routine aminotransferase. It is the first-line marker of hepatocellular damage, interpreted with AST, ALP, GGT, and bilirubin and the AST:ALT ratio to classify liver injury, screen for steatotic liver disease, and monitor hepatotoxic therapy.

BML-GAS-052View reference →

metabolic diabetes

CMP

The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.

BML-MET-003View reference →